Russia's R-Pharm to start production of generic copy of AbbVie's Sevoran
Russian drugmaker R-Pharm is expanding its line of generics of original drugs by starting production ofan analogue of Sevoran (sevoflurane), which is an anesthetic produced by the US biopharma company AbbVie (NYSE: ABBV), reports The Pharma Letter's loical correspondent.
To date, R-Pharm has registered a generic of the drug under the Sevofluran brand name, planning to begin its full-scale production at its factory in the Russian city of Yaroslavl. The same facility is currently conducts the secondary packaging of the original Sevoran drug in Russia.
In the case of AbbVie, the company announced localization of the production of Sevoran on the full-cycle basis in Russia at the facilities of R-Pharm in 2015. The launch of production is scheduled for 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze